These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 31527214)
1. Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour. Versluis J; Valk G; van Rossum H; Tesselaar M BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527214 [TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity. Versluis JM; Brandsma D; van den Berg JG; Tesselaar M BMJ Case Rep; 2018 Nov; 2018():. PubMed ID: 30391925 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443 [TBL] [Abstract][Full Text] [Related]
4. Metastatic neuroendocrine pancreatic tumor - Case report. Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066 [No Abstract] [Full Text] [Related]
5. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A; Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056 [TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Flaum N; Valle JW; Mansoor W; McNamara MG Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069 [TBL] [Abstract][Full Text] [Related]
8. Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases. Jannin A; Espiard S; Benomar K; Do Cao C; Mycinski B; Porte H; D'Herbomez M; Penel N; Vantyghem MC Ann Endocrinol (Paris); 2019 Feb; 80(1):21-25. PubMed ID: 29555080 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749 [TBL] [Abstract][Full Text] [Related]
10. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Costa FP; Gumz B; Pasche B Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923 [TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycemia and hypokalemia in association with liver metastases of gastric cancer. Kato A; Bando E; Shinozaki S; Yonemura Y; Aiba M; Fukuda I; Hizuka N; Kameya T Intern Med; 2004 Sep; 43(9):824-8. PubMed ID: 15497518 [TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133 [TBL] [Abstract][Full Text] [Related]
14. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. de Groot JW; Rikhof B; van Doorn J; Bilo HJ; Alleman MA; Honkoop AH; van der Graaf WT Endocr Relat Cancer; 2007 Dec; 14(4):979-93. PubMed ID: 18045950 [TBL] [Abstract][Full Text] [Related]
15. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Rikhof B; van Doorn J; Suurmeijer AJH; Rautenberg MW; Groenen PJTA; Verdijk MAJ; Jager PL; de Jong S; Gietema JA; van der Graaf WTA Ann Oncol; 2009 Sep; 20(9):1582-1588. PubMed ID: 19276395 [TBL] [Abstract][Full Text] [Related]
18. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183 [TBL] [Abstract][Full Text] [Related]
19. Non islet cell tumor hypoglycaemia in a metastatic Leydig cell tumor. Mukherjee S; Diver M; Weston PJ Acta Oncol; 2005; 44(7):761-3. PubMed ID: 16227169 [TBL] [Abstract][Full Text] [Related]
20. Update in the Therapy of Advanced Neuroendocrine Tumors. Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]